Project 1 will test the hypothesis that poststroke dementia is a function of preclinical Alzheimer's disease (AD). The prediction from this hypothesis is that poststroke dementia will be disproportionately represented in stroke individuals with preclinical AD in comparison with stroke individuals without preclinical AD.
The Specific Aims of the project are to: 1. Over 3.5 years, enroll a cohort of 240 older adults, age 65 years and older, hospitalized with acute ischemic stroke and obtain baseline demographic data, medical history, neurological status, neuropsychological evaluation, prestroke cognitive and functional status, and blood for Project 2 (plasma) and Project 4 (DMA). 2. In this hospitalized cohort, obtain magnetic resonance imaging (MRI) to characterize cerebral ischemic lesions and positron emission tomography (PET) with the [11C]benzothiazole amyloid tracer, Pittsburgh Compound B (PIB), to determine the presence or absence of preclinical AD (as defined by a positive PIB scan). 3. Every three months after discharge, maintain telephone contact with the patient and their families to monitor intercurrent events and maintain compliance. 4. One year poststroke, assess all patients with the Clinical Core clinical and neuropsychological batteries and derive a Clinical Dementia Rating (CDR) for correlation with baseline PIB status (CDR > 0.5 will be considered evidence for dementia). 5. Obtain MRI one year poststroke to evaluate potential new ischemic lesions;obtain blood for plasma biomarkers (Project 2);enroll patients into Project 3;and follow all patients annually with clinical and cognitive assessments and obtain voluntary consent for autopsy. This project directly addresses the overall aim of the program project grant, to characterize preclinical AD. It further addresses the unresolved issue of why dementia occurs in some, but not all, individuals with stroke. This project uses resources from all Cores. It also interacts with each of the individual projects

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG003991-30
Application #
8425014
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
2014-12-31
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
30
Fiscal Year
2013
Total Cost
$146,260
Indirect Cost
$50,037
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Cruchaga, Carlos; Del-Aguila, Jorge L; Saef, Benjamin et al. (2018) Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. Alzheimers Dement 14:205-214
Maxwell, Taylor J; Corcoran, Chris; Del-Aguila, Jorge L et al. (2018) Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels. Alzheimers Res Ther 10:86
Kinnunen, Kirsi M; Cash, David M; Poole, Teresa et al. (2018) Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study. Alzheimers Dement 14:43-53
Brainstorm Consortium (see original citation for additional authors) (2018) Analysis of shared heritability in common disorders of the brain. Science 360:
Ibanez, Laura; Dube, Umber; Davis, Albert A et al. (2018) Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease. Front Neurosci 12:230
Schultz, Stephanie A; Gordon, Brian A; Mishra, Shruti et al. (2018) Widespread distribution of tauopathy in preclinical Alzheimer's disease. Neurobiol Aging 72:177-185
Broce, Iris; Karch, Celeste M; Wen, Natalie et al. (2018) Correction: Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. PLoS Med 15:e1002504
Javaherian, Kavon; Newman, Brianne M; Weng, Hua et al. (2018) Examining the Complicated Relationship Between Depressive Symptoms and Cognitive Impairment in Preclinical Alzheimer Disease. Alzheimer Dis Assoc Disord :
Liao, Fan; Li, Aimin; Xiong, Monica et al. (2018) Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. J Clin Invest 128:2144-2155
Jansen, Willemijn J; Ossenkoppele, Rik; Tijms, Betty M et al. (2018) Association of Cerebral Amyloid-? Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry 75:84-95

Showing the most recent 10 out of 911 publications